ANI Pharmaceuticals (NASDAQ: ANIP) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare ANI Pharmaceuticals to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ANI Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 1 2 0 2.67
ANI Pharmaceuticals Competitors 475 2254 6144 119 2.66

ANI Pharmaceuticals presently has a consensus price target of $67.33, indicating a potential upside of 16.92%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 1.56%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe ANI Pharmaceuticals is more favorable than its rivals.

Earnings & Valuation

This table compares ANI Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
ANI Pharmaceuticals $158.12 million $59.01 million 125.20
ANI Pharmaceuticals Competitors $207.75 million -$2.17 million 0.61

ANI Pharmaceuticals’ rivals have higher revenue, but lower earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

ANI Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals’ rivals have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.

Insider and Institutional Ownership

55.8% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 31.8% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares ANI Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 3.35% 22.70% 11.48%
ANI Pharmaceuticals Competitors -3,984.80% -117.96% -44.22%


ANI Pharmaceuticals beats its rivals on 10 of the 13 factors compared.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.